In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche/Ventana

This article was originally published in The Gray Sheet

Executive Summary

Roche continues pursuit of diagnostic firm Ventana Medical systems, extending its $75-per-share offer to acquire the company until Aug. 23. The drug and diagnostic giant initiated a hostile takeover of Ventana in June, originally extending the offer, equal to about $3 billion in total, through July 26. Ventana's board says the bid - a 44% premium over Ventana's June 22 stock price - is "wholly inadequate." Since the original offer, Ventana's shares have shot up about 60%, closing at $83.02 on July 27. The deal would give Roche entry into the $1 billion tissue-based testing market and provide diagnostic platforms to pair with its targeted cancer drugs (1"The Gray Sheet" July 2, 2007, p. 10)...

You may also be interested in...



Roche Seeks Diagnostics To Pair With Cancer Drugs In $3 Billion Ventana Bid

Roche's $3 billion hostile takeover bid for Ventana Medical Systems is aimed at providing the drug and diagnostics giant with platform technology for tissue-based diagnostic tests to pair with targeted cancer drugs, the company says

GNC In Rough Seas From COVID-19 Pandemic; Vitamin Shoppe Safe In Port Under New Owner

GNC announces "significant" store and management staff furloughs and other cost-cutting moves "to protect the long-term prospects for the business." Vitamin Shoppe told customers that its stores remain open though it reduced business hours.

QUOTED. 7 April 2020. Surendar Magar.

California-based biosensor patch company LifeSignals Group plans to file for an emergency use authorization from the US FDA for a new patch that can monitor vital signs to help individuals decide when to seek the help of a health care provider. See what LifeSignals’ CEO Surendar Magar said about it here.

UsernamePublicRestriction

Register

MT025083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel